An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice

By K. Podsypanina, Richard T. Lee, C. Politis, Ian Hennessy, Allison Crane, J. Puc, M. Neshat, Hong Wang, J. Gibbons, P. Frost and 7 more. Proceedings of the National Academy of Sciences of the United States of America, 2001

620 citations recorded by the source corpus.

Subfields: Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/835f15c9b4fd5626d8010694c4bbda50b2f8a463

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. David M. Sabatini
2. K. Guan
3. Michael N. Hall
4. B. Manning
5. M. Laplante
6. J. Blenis
7. N. Hay
8. Nahum Sonenberg

In Pathology and Forensic Medicine

1. David M. Sabatini
2. K. Guan
3. J. Blenis
4. R. Shaw

Citations in the corpus

• Upstream and downstream of mTOR. (2004, background): “Also, the administration of CCI-779 to PTEN heterozygous mice, which develop multiple neoplasia, attenuates tumor development (Podsypanina et al. 2001).”
• Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. (2006, background): “Predictors of tumor sensitivity to rapamycin are not available, although recent work indicates that tumors missing the PTEN or VHL tumor suppressors may be particularly sensitive to the drug (Neshat et al., 2001; Podsypanina et al., 2001; Thomas et al., 2006).”
• Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. (2004, background): “In PTEN heterozygous mice with uterine and adrenal medullary tumors, treatment with CCI-779 produces significant reductions in tumor size [25], which suggest that CCI-779 may be useful in the treatment of human tumors that contain mutations in PTEN.”
• TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling (2002, background): “The importance of mTOR in tumorigenesis is supported by the fact that rapamycin inhibits tumour growt”
• TOR signalling in bugs, brain and brawn (2003, background): “pl?O00633">PTEN )-deficient cancer cells, in which the PI3K pathway is activated owing to the upregulation of the lipid second messenger phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P 3 ), indicate that inhibition of mTOR blocks signalling through the PI3K pathwa”